http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108913655-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2509-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0657 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-077 |
| filingDate | 2018-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108913655-B |
| titleOfInvention | A method for establishing a "human-derived" cardiac hypertrophy model based on pluripotent stem cell technology |
| abstract | The invention discloses a method for establishing a "human-derived" myocardial hypertrophy model based on pluripotent stem cell technology. In this method, cardiomyocytes differentiated from pluripotent stem cells that have been cultured for about 30 days are resuspended and then seeded into a 12-well plate, with 1.5×10 6 cells per well. About 24 hours after the cells adhere to the wall, the phorbol-12-myristate-13-acetate dosing experiment can be started, and the induction is carried out at a concentration of 1 μM for 4 days. The invention can establish a stable human-derived myocardial hypertrophy model based on the pluripotent stem cell technology, and the shape and function conform to the characteristics of myocardial cell hypertrophy, the operation is convenient, and the modeling success rate is high. |
| priorityDate | 2018-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 111.